Key Points
- Director John Thomas sold 10,000 shares of Genelux (GNLX) on Dec. 1 at an average price of $5.00 for $50,000, reducing his stake by 1.99% to 492,784 shares; the transaction was disclosed in an SEC filing.
- Wall Street shows a mixed but overall positive view with three Buy and one Sell rating (average rating "Moderate Buy") and an average price target of about $21.00, while the stock trades around $4.73 with a 50-day/200-day moving average of $5.70/$4.10 and a market cap near $180 million.
- Genelux is a clinical-stage biopharma developing Olvi-Vec for hard-to-treat solid tumors; institutional investors own roughly 37.3% of the shares, and several funds increased their positions in the most recent quarter.
Genelux Corporation (NASDAQ:GNLX - Get Free Report) Director John Thomas sold 10,000 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $5.00, for a total value of $50,000.00. Following the transaction, the director owned 492,784 shares of the company's stock, valued at $2,463,920. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Genelux Stock Performance
Shares of NASDAQ:GNLX opened at $4.73 on Wednesday. The company has a 50 day moving average price of $5.70 and a two-hundred day moving average price of $4.10. The company has a market capitalization of $179.98 million, a PE ratio of -5.38 and a beta of 0.06. Genelux Corporation has a 52 week low of $1.99 and a 52 week high of $8.53.
Genelux (NASDAQ:GNLX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02. On average, sell-side analysts forecast that Genelux Corporation will post -0.88 earnings per share for the current year.
Wall Street Analysts Forecast Growth
GNLX has been the subject of several research analyst reports. Loop Capital set a $16.00 price target on shares of Genelux in a report on Tuesday, October 21st. Weiss Ratings restated a "sell (e+)" rating on shares of Genelux in a research report on Wednesday, October 8th. Maxim Group set a $20.00 target price on Genelux in a research report on Tuesday, October 21st. Finally, Lake Street Capital started coverage on Genelux in a research note on Tuesday, October 21st. They set a "buy" rating and a $16.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $21.00.
View Our Latest Research Report on GNLX
Hedge Funds Weigh In On Genelux
Institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP raised its position in Genelux by 140.3% in the third quarter. Susquehanna International Group LLP now owns 52,383 shares of the company's stock worth $220,000 after acquiring an additional 30,583 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of Genelux by 101.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 37,224 shares of the company's stock worth $156,000 after acquiring an additional 18,734 shares in the last quarter. Creative Planning raised its position in shares of Genelux by 4.7% in the 3rd quarter. Creative Planning now owns 46,108 shares of the company's stock worth $194,000 after purchasing an additional 2,084 shares during the last quarter. Woodward Diversified Capital LLC grew its holdings in shares of Genelux by 3.7% in the third quarter. Woodward Diversified Capital LLC now owns 1,844,099 shares of the company's stock worth $7,745,000 after acquiring an additional 65,813 shares during the period. Finally, 5T Wealth LLC boosted its stake in shares of Genelux by 33.9% during the 3rd quarter. 5T Wealth LLC now owns 24,101 shares of the company's stock worth $101,000 after acquiring an additional 6,100 shares during the last quarter. 37.33% of the stock is owned by institutional investors and hedge funds.
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
